Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.
Fiche publication
Date publication
mars 2018
Journal
Alimentary pharmacology & therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos B, Serrero M, Buisson A, Amiot A, Fumery M, Roblin X, Peyrin-Biroulet L, Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, Laharie D, Pariente B,
Lien Pubmed
Résumé
Long-term outcome of ustekinumab in Crohn's disease (CD) has not been evaluated.
Mots clés
Adult, Cohort Studies, Crohn Disease, drug therapy, Drug Resistance, drug effects, Endoscopy, Female, Follow-Up Studies, Humans, Male, Pregnancy, Retrospective Studies, Time Factors, Treatment Outcome, Tumor Necrosis Factor-alpha, therapeutic use, Ustekinumab, administration & dosage
Référence
Aliment. Pharmacol. Ther.. 2018 Mar;47(5):588-595